$294.00
0.18% yesterday
NYSE, Nov 25, 10:12 pm CET
ISIN
US0311621009
Symbol
AMGN
Sector
Industry

Amgen Stock price

$294.00
-22.98 7.25% 1M
-11.84 3.87% 6M
+5.98 2.08% YTD
+29.73 11.25% 1Y
+90.03 44.14% 3Y
+59.46 25.35% 5Y
+131.76 81.21% 10Y
NYSE, Closing price Mon, Nov 25 2024
-0.53 0.18%
ISIN
US0311621009
Symbol
AMGN
Sector
Industry

Key metrics

Market capitalization $158.03b
Enterprise Value $209.42b
P/E (TTM) P/E ratio 37.64
EV/FCF (TTM) EV/FCF 33.33
EV/Sales (TTM) EV/Sales 6.48
P/S ratio (TTM) P/S ratio 4.89
P/B ratio (TTM) P/B ratio 20.99
Dividend yield 3.06%
Last dividend (FY24) $9.00
Revenue growth (TTM) Revenue growth 21.38%
Revenue (TTM) Revenue $32.32b
EBIT (operating result TTM) EBIT $6.51b
Free Cash Flow (TTM) Free Cash Flow $6.28b
Cash position $9.01b
EPS (TTM) EPS $7.81
P/E forward 32.29
P/S forward 4.76
EV/Sales forward 6.31
Short interest 1.64%
Show more

Create a Free Account to create an Amgen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Amgen Stock Analysis

Analyst Opinions

34 Analysts have issued a Amgen forecast:

15x Buy
44%
17x Hold
50%
2x Sell
6%

Analyst Opinions

34 Analysts have issued a Amgen forecast:

Buy
44%
Hold
50%
Sell
6%

Financial data from Amgen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
32,324 32,324
21% 21%
100%
- Direct Costs 12,858 12,858
81% 81%
40%
19,466 19,466
0% 0%
60%
- Selling and Administrative Expenses 1,619 1,619
40% 40%
5%
- Research and Development Expense 5,762 5,762
26% 26%
18%
12,085 12,085
1% 1%
37%
- Depreciation and Amortization 5,575 5,575
55% 55%
17%
EBIT (Operating Income) EBIT 6,510 6,510
25% 25%
20%
Net Profit 4,230 4,230
44% 44%
13%

In millions USD.

Don't miss a Thing! We will send you all news about Amgen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amgen Stock News

Positive
CNBC
23 minutes ago
Amgen said its experimental weight loss injection helped patients lose up to 20% of their weight on average after a year, with no plateau, in a critical mid-stage trial. But the results appear to be at the low end of Wall Street's expectations.
Positive
Reuters
27 minutes ago
Amgen's experimental drug MariTide led to average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 people who were overweight or obese, the company said on Tuesday.
Neutral
PRNewsWire
32 minutes ago
MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight MariTide is the First Obesity Treatment With Monthly or Less Frequent Dosing to Demonstrate Safe and Effective Weight Loss in a Phase 2 Study In People With Type 2 Diabetes Living With Obesity or Overweight MariTide Demonstrated up to ~17% Average Weight Los...
More Amgen News

Company Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Head office United States
CEO Robert Bradway
Employees 26,700
Founded 1980
Website www.amgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today